Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeradigmMDRX +3.05%17 EV-to-FCF is 5.60 as of Jul. 14, 2026. GuruFocus rates MDRX with a GF Score™ of 17/100. Among 404 Healthcare Providers & Services companies, Veradigm ranks better than 88.12% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Veradigm's Enterprise Value is $466.7 Mil.
Veradigm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 was $83.3 Mil. Therefore, Veradigm's EV-to-FCF for today is 5.60.
The historical rank and industry rank for Veradigm's EV-to-FCF or its related term are showing as below:
MDRX'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 5.89
Current: 5.6
During the past 13 years, the highest EV-to-FCF of Veradigm was 5.89. The lowest was 0.00. And the median was 0.00.
MDRX's EV-to-FCF is ranked better than 88.12% of 404
companies
in the Healthcare Providers & Services industry
Industry Median: 18.01
vs MDRX: 5.60
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Veradigm's share price for today is $4.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Veradigm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-2.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Veradigm EV-to-FCF Related Terms
Veradigm EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Veradigm's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Veradigm's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veradigm EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veradigm's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Veradigm's EV-to-FCF falls into.
Veradigm's current Enterprise Value is $466.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Veradigm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2022 was $83.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veradigm (MDRX) has a EV-to-FCF of 5.60 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Veradigm and its competitors. According to the industry distribution chart, Veradigm ranks #48 out of 404 companies in the Healthcare Providers & Services industry, placing it in the top 11.9%.
Is Veradigm's EV-to-FCF too high?
Veradigm's current EV-to-FCF is 5.60. The Healthcare Providers & Services industry median EV-to-FCF is 18.01. Veradigm's value of 5.60 is 68.9% below this industry median. Based on the distribution chart, Veradigm ranks #48 out of 404 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Veradigm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's EV-to-FCF compare to CTEV and EVH?
According to the Healthcare Providers & Services industry distribution chart, Veradigm ranks #48 out of 404 companies for EV-to-FCF. This places Veradigm in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 18.01. Veradigm's value of 5.60 is 68.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 18.01, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veradigm's current EV-to-FCF of 5.60 is 68.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Veradigm and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 18.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veradigm's current EV-to-FCF is 5.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (MDRX) has a current EV-to-FCF of 5.60. The current EV-to-FCF is 5.60 and 68.9% below the Healthcare Providers & Services industry median of 18.01. Veradigm's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Veradigm (MDRX), the current EV-to-FCF is 5.60 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
17GF Score
Get the complete analysis for MDRX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDRX has been successfully added to your 
